Korro Bio, Inc.
Korro Bio, Inc. (Nasdaq: KRRO) is a biopharmaceutical company developing genetic medicines that use oligonucleotides to harness the body’s natural RNA-editing process and make targeted, transient A-to-I changes to RNA. Its OPERA platform combines ADAR biology, oligonucleotide chemistry, machine-learning-based design… From the company’s description.
In fiscal 2025, Korro Bio, Inc. reported revenue of $6.39M, up 181.5% from fiscal 2024, and a net loss of $117.26M. Operations used $78.56M in cash. Over the twelve months to Sep 30, 2026, revenue was $1.29M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Korro Bio, Inc. does
In the company’s own words
Korro Bio, Inc. (Nasdaq: KRRO) is a biopharmaceutical company developing genetic medicines that use oligonucleotides to harness the body’s natural RNA-editing process and make targeted, transient A-to-I changes to RNA. Its OPERA platform combines ADAR biology, oligonucleotide chemistry, machine-learning-based design and established delivery approaches. The company’s programs aim to repair or modify proteins to address rare and prevalent diseases, with lead candidate KRRO-121 designed to enhance ammonia clearance for hyperammonemia, including in urea cycle disorders and hepatic encephalopathy. Other wholly owned programs target alpha-1 antitrypsin deficiency, the AMPKγ1 pathway for longevity and liver health, and ALS; a collaboration with Novo Nordisk covers up to two additional programs. All programs are in research or preclinical development. Korro reported $[not provided] in revenue for fiscal 2025. Its website is not stated in the provided filing text.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1703647
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Korro Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Korro Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Korro Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Korro Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Korro Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”